Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

342 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
RBM17 Expression Is Associated With the Efficacy of ICI Monotherapy in NSCLC With Low PD-L1 Expression.
Nagamine H, Yashiro M, Yoshimoto N, Izumi M, Sugimoto A, Nakahama K, Ogawa K, Matsumoto Y, Sawa K, Tani Y, Kaneda H, Mitsuoka S, Yamada K, Watanabe T, Aasai K, Fukumura K, Mayeda A, Kawaguchi T. Nagamine H, et al. Among authors: yoshimoto n. Anticancer Res. 2023 Oct;43(10):4663-4672. doi: 10.21873/anticanres.16662. Anticancer Res. 2023. PMID: 37772582
SP142 evaluation contributes to the prediction of immune checkpoint inhibitor efficacy in non-small cell lung cancer with high PD-L1 expression assessed by 22C3.
Nakahama K, Osawa M, Izumi M, Yoshimoto N, Sugimoto A, Nagamine H, Ogawa K, Matsumoto Y, Sawa K, Tani Y, Kaneda H, Mitsuoka S, Watanabe T, Asai K, Kawaguchi T. Nakahama K, et al. Among authors: yoshimoto n. Transl Lung Cancer Res. 2022 Dec;11(12):2438-2451. doi: 10.21037/tlcr-22-496. Transl Lung Cancer Res. 2022. PMID: 36636414 Free PMC article.
Vascular endothelial growth factor receptor 2 expression and immunotherapy efficacy in non-small cell lung cancer.
Nakahama K, Kaneda H, Osawa M, Fukui M, Izumi M, Yoshimoto N, Sugimoto A, Nagamine H, Ogawa K, Matsumoto Y, Sawa K, Tani Y, Mitsuoka S, Watanabe T, Asai K, Kawaguchi T. Nakahama K, et al. Among authors: yoshimoto n. Cancer Sci. 2022 Sep;113(9):3148-3160. doi: 10.1111/cas.15464. Epub 2022 Jul 18. Cancer Sci. 2022. PMID: 35722982 Free PMC article.
Association of thyroid transcription factor-1 with the efficacy of immune-checkpoint inhibitors in patients with advanced lung adenocarcinoma.
Nakahama K, Kaneda H, Osawa M, Izumi M, Yoshimoto N, Sugimoto A, Nagamine H, Ogawa K, Matsumoto Y, Sawa K, Tani Y, Mitsuoka S, Watanabe T, Asai K, Kawaguchi T. Nakahama K, et al. Among authors: yoshimoto n. Thorac Cancer. 2022 Aug;13(16):2309-2317. doi: 10.1111/1759-7714.14560. Epub 2022 Jul 8. Thorac Cancer. 2022. PMID: 35808895 Free PMC article.
Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.
Matsumoto Y, Sawa K, Fukui M, Oyanagi J, Yoshimoto N, Suzumura T, Watanabe T, Kaneda H, Mitsuoka S, Asai K, Kimura T, Yamamoto N, Hirata K, Koh Y, Kawaguchi T. Matsumoto Y, et al. Among authors: yoshimoto n. Lung Cancer. 2020 Jan;139:80-88. doi: 10.1016/j.lungcan.2019.10.029. Epub 2019 Nov 2. Lung Cancer. 2020. PMID: 31751804
342 results